The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2018 | iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, of Barts Cancer Institute, London, UK, chairs a discussion with Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, and Caron Jacobson, MD, from the Dana-Farber Cancer Institute, Boston, MA, on the key news from day 2 of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France. The experts explore precision medicine and bridging treatment to CAR T-cell therapy; exciting strategies include combinations with polatuzumab vedotin or ibrutinib pre-treatment. A highlighted consideration is how prior treatment with common drugs affect later T-cell collection from patients.
